LYFIX — AlphaCentric Life Sciences and Healthcare Fund
Data updated: 2026-08-27
LYFIX — AlphaCentric Life Sciences and Healthcare Fund. Holdings, fees, performance and SEC filings.
LYFIX Fund Overview
LYFIX — AlphaCentric Life Sciences and Healthcare Fund is a US mutual fund managed by Mutual Fund Series Trust, categorised as United States Multi-Cap / All-Cap Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Mutual Fund Series Trust
- Category: United States Multi-Cap / All-Cap Growth Health Care Equity
- Assets under management: $46.65M
- 1-year return: 54.7%
- Ticker: LYFIX
- SEC CIK: 0001355064
- SEC series ID: S000067055
- Share class ID: C000215730
LYFIX Holdings
Top 10 holdings of AlphaCentric Life Sciences and Healthcare Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Gilead Sciences, Inc. | 5.53% |
| Vertex Pharmaceuticals, Inc. | 5.33% |
| Astrazeneca PLC | 4.63% |
| First American Funds, Inc. | 4.26% |
| Roivant Sciences Ltd. | 3.67% |
| Argenx SE | 3.59% |
| Neurocrine Biosciences, Inc. | 3.51% |
| Incyte Corp. | 3.51% |
| Axsome Therapeutics, Inc. | 3.43% |
| Apogee Therapeutics, Inc. | 3.28% |
LYFIX Portfolio Allocation
Asset-class allocation of AlphaCentric Life Sciences and Healthcare Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 95.8% |
| Cash & Equivalents | 4.3% |
LYFIX Performance
Total returns for LYFIX (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 17.4% |
| 1 year | 54.7% |
| 3 years (annualised) | 13.5% |
| 5 years (annualised) | 7.9% |
LYFIX Risk Information
Risk metrics for LYFIX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 17.7%
LYFIX Costs and Fees
LYFIX costs about $141 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.41%
- Gross expense ratio: 2.08%
- Portfolio turnover: 107%
- Brokerage commissions: 15.33 bps of average net assets (SEC N-CEN)
LYFIX Cashflows
Over the 12 months to 2026-06, AlphaCentric Life Sciences and Healthcare Fund had net outflows of $3.52M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | $256.27K |
| 2026-05 | $120.29K |
| 2026-04 | −$78.28K |
| 2026-03 | $57.27K |
| 2026-02 | −$118.39K |
| 2026-01 | $2.48M |
LYFIX Debt Constituents
No individual debt constituents are reported in AlphaCentric Life Sciences and Healthcare Fund's latest SEC N-PORT filing.
LYFIX Prospectus and SEC Filings
Official AlphaCentric Life Sciences and Healthcare Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-07-28
- Prospectus (485BPOS) — filed 2025-07-28
- Prospectus supplement (497) — filed 2024-08-05
- Portfolio holdings (N-PORT) — filed 2026-08-27
- Portfolio holdings (N-PORT) — filed 2026-05-29
- Portfolio holdings (N-PORT) — filed 2026-02-26
- Annual census (N-CEN) — filed 2026-06-12
- Annual census (N-CEN) — filed 2025-06-13
Related Funds
Other United States Multi-Cap / All-Cap Growth Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.